Conservative surgery in patients with malignant ovarian germ cell tumours

Conservative surgery with adjuvant chemotherapy has made the preservation of fertility even in patient with advanced disease. The increase in cure rate has shifted to research for the long term menstrual reproductive and gynecologic outcome in these patients. The current study is retrospective for 25 cases of ovarian malignant germ cell tumor from January 2006 to January 2011, at El Hussian and Sayed Galal University Hospitals. The uterus and contralateral ovary were retained to preserve ovarian function with or without chemotherapy, followed up for two years. The mean age of most patients ranged from 15-28 years [average 21.5 years]. According to International Federation of Gynecology and Obstetrics, the histological subtypes were ten dysgerminoma [40%]. Five immature teratoma [20%], three endodermal sinus tumor [12%], four mixed germ cell tumor [16%] three embryonic cell tumours [12%]. Stage I: tumors 15 cases [60%], Stage II: tumors one case [4%], Stage III tumors 6 cases [24%], Stage IV tumors 3 cases [12%]. Adjuvant chemotherapy was administered to 15 cases 60% and followed up for two years. There were two recurrences, one died at 7[th] day postoperative of massive pulmonary embolism with past history of D.V.T, five healthy live births in the chemotherapy group without birth defects, and one infertility case 4%

Risk factors of endometrial polyps in tamoxifen treated postmenopausal breast cancer patients

Endometrial polyps are the most common endometrial pathology associated with postmenpausal tamoxifen exposure. Up to 3% of these polyp may show malignant changes. is the endometrial cancer has predisposition or risk factors in postmenpausal tamoxifen receiving breast cancer patients risk factors for endometrial polyps. This is prospective study done at El-Hussien and Sayed Galal University hospitals the data were collected from medical records after the patient consent to be involved in this study we have two groups group I in which the hystrescope reveals the endometrial polyp at 6 months of tamoxifen receiving in postmenopausal breast carcinoma patients. Group II in which the hystrescope reveals nothing each group has 20 patients and follow up for one year. age at menopause was significantly older, increased duration of breast disease increased body weight, increased endometrial thickness. In group I if these compared by group II. Various factors such as old age at menopause, increased duration of breast disease increased body weight. Thicker endometri urn may contri bute to the prediction of increased risk of development of endometrial polyp in postmenopausal patients with breast carcinoma treated by tamoxifen